Resistance mutation info of target

Target General Information
Target ID T12355
Target Name G1/S-specific cyclin D1 (CCND1) Target Info
Gene Name CCND1
Species Homo sapiens
Uniprot ID CCND1_HUMAN
Sequence MEHQLLCCEVETIRRAYPDANLLNDRVLRAMLKAEETCAPSVSYFKCVQKEVLPSMRKIV
ATWMLEVCEEQKCEEEVFPLAMNYLDRFLSLEPVKKSRLQLLGATCMFVASKMKETIPLT
AEKLCIYTDNSIRPEELLQMELLLVNKLKWNLAAMTPHDFIEHFLSKMPEAEENKQIIRK
HAQTFVALCATDVKFISNPPSMVAAGSVVAAVQGLNLRSPNNFLSYYRLTRFLSRVIKCD
PDCLRACQEQIEALLESSLRQAQQNMDPKAAEEEEEEEEEVDLACTPTDVRDVDI [Hom
o sapiens]
Drug Resistance Mutation and Corresponding Drugs
Ref 524263ClinicalTrials.gov (NCT01833039) An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma. U.S. National Institutes of Health.
Ref 541962(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6912).
Ref 551043Janssen's IMBRUVICA (ibrutinib) Receives Additional European Commission Approval for the Treatment of Waldenstrom's Macroglobulinemia. Janssen-Cilag International NV (Janssen). Jul 10, 2015.
Mutation Info Missense: C47S
Drugs
Drug Name Ibrutinib Drug Info [1559235]
Targeted Disease Refractory hematologic malignancy
Mutation Info Missense: T286A
Drugs
Drug Name Ibrutinib Drug Info [1559235]
Targeted Disease Refractory hematologic malignancy
Mutation Info Missense: Y44D
Drugs
Drug Name Ibrutinib Drug Info [1559235]
Targeted Disease Refractory hematologic malignancy
Reference
Ref 1559235CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma.Oncotarget.2016 Nov 8;7(45):73558-73572.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.